These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 39199421)

  • 41. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
    Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
    Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in CAR-NK cell therapy for hematological malignancies.
    Yang R; Yang Y; Liu R; Wang Y; Yang R; He A
    Front Immunol; 2024; 15():1414264. PubMed ID: 39007146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023.
    Li W; Feng J; Peng J; Zhang X; Aziz AUR; Wang D
    Hum Vaccin Immunother; 2024 Dec; 20(1):2415187. PubMed ID: 39414236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges.
    Wang L; Dou M; Ma Q; Yao R; Liu J
    Int Immunopharmacol; 2019 Sep; 74():105695. PubMed ID: 31254958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NK cell based immunotherapy against oral squamous cell carcinoma.
    Zhang Y; Xie J; Wu H; Huang J; Zheng D; Wang S; Jia X; He Z; Gong Y; Ju L; Sun Q
    Front Immunol; 2024; 15():1440764. PubMed ID: 39192980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical development of natural killer cells expressing chimeric antigen receptors.
    Golden RJ; Fesnak AD
    Transfus Apher Sci; 2021 Feb; 60(1):103065. PubMed ID: 33468407
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synapse-tuned CARs enhance immune cell anti-tumor activity.
    Chockley PJ; Ibanez-Vega J; Krenciute G; Talbot LJ; Gottschalk S
    Nat Biotechnol; 2023 Oct; 41(10):1434-1445. PubMed ID: 36732477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CAR-NK Cells in the Treatment of Solid Tumors.
    Wrona E; Borowiec M; Potemski P
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
    Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
    Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CAR-NK cell therapy in AML: Current treatment, challenges, and advantage.
    Bahramloo M; Shahabi SA; Kalarestaghi H; Rafat A; Mazloumi Z; Samimifar A; Asl KD
    Biomed Pharmacother; 2024 Aug; 177():117024. PubMed ID: 38941897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natural Killer Cells in Cancer and Cancer Immunotherapy.
    Raskov H; Orhan A; Salanti A; Gaggar S; Gögenur I
    Cancer Lett; 2021 Nov; 520():233-242. PubMed ID: 34302920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
    Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
    Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.
    Zhang J; Zheng H; Diao Y
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
    Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
    Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overcoming tumor resistance mechanisms in CAR-NK cell therapy.
    Valeri A; García-Ortiz A; Castellano E; Córdoba L; Maroto-Martín E; Encinas J; Leivas A; Río P; Martínez-López J
    Front Immunol; 2022; 13():953849. PubMed ID: 35990652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.